Director/10% Owner Sells $3.16M in Atara Biotherapeutics Shares Amidst Delisting Notice
ATRA has more than doubled off its 52-week low of $3.92.
Summary
A director and 10% owner sold over $3.16 million worth of Atara Biotherapeutics shares, a significant disposition amidst the company's ongoing financial and regulatory challenges, creating mixed insider sentiment.
Key Events · Ownership and Investor Activity · ATRA
-
Significant Insider Sale
James Huang, a Director and 10% Owner through Panacea Innovation Ltd, sold 313,446 shares of common stock for a total of $3,165,021 at an average price of $10.10 per share on May 7, 2026.
-
Substantial Stake Reduction
This transaction represents a significant portion of Atara Biotherapeutics' market value and a reduction of over 23% of the reporting owner's total holdings.
-
Context of Company Distress
The sale follows recent negative developments, including a Nasdaq delisting notice on May 1st and a going concern warning issued in the March 16th 10-K filing, highlighting severe financial and operational challenges.
-
Conflicting Insider Activity
This significant sale by a director contrasts with a substantial open-market purchase by another 10% owner, EcoR1 Capital, reported on the same day, creating mixed signals from major investors.
Analysis · ATRA · Life Sciences
This substantial sale by a director and 10% owner, representing a significant portion of the company's market value and nearly a quarter of their total holdings, is a strong negative indicator. It occurs shortly after the company received a Nasdaq delisting notice and issued a going concern warning, suggesting a lack of confidence from a key insider during a critical period. This sale also creates conflicting signals, as another 10% owner reported a substantial purchase on the same day.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.9% of the 285 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRA was trading at $9.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.